Roche Acquired Rights to New Obesity Drug Candidate
The company secured an investigational RNAi treatment to expand its presence in the competitive weight-loss market.
Updated on Oct. 13, 2026 in Weight Loss
Live Poll
Do you trust that new pharmaceutical obesity treatments will improve long-term public health?
Roche has entered into a licensing agreement with Rona Therapeutics for an investigational RNAi drug targeting activin receptor-like kinase 7 (ALK7). This move marks a strategic effort by the company to enter the obesity treatment landscape.
Why it matters
The deal signals Roche's attempt to capture a share of the weight-loss market, which is currently dominated by therapies from Eli Lilly and Novo Nordisk. This new candidate uses RNA interference technology, a different approach than existing GLP-1 medications.
The licensing agreement covers a potential value of $1.16 billion, including an upfront payment of $100 million and $1.06 billion in future milestone payments. The efficacy and clinical safety of this RNAi candidate remain under investigation.
The players
Roche
A global healthcare company focused on diagnostics and pharmaceuticals, including treatments for metabolic and chronic diseases.
Rona Therapeutics
A biotechnology firm specializing in the development of RNAi-based therapies for various conditions.
Eli Lilly
A pharmaceutical manufacturer known for its production of GLP-1 receptor agonist medications for diabetes and weight management.
Novo Nordisk
A global healthcare company and leading manufacturer of obesity and diabetes medications.
The details
The investigational drug works by targeting activin receptor-like kinase 7, a protein involved in metabolic regulation. By utilizing RNA interference (RNAi), the therapy is designed to silence or reduce the expression of the gene encoding ALK7. This approach aims to influence metabolic pathways differently than standard incretin-based obesity medications.
Timeline
September 2026: Roche reported mid-stage data for enicepatide.
October 13, 2026: Roche and Rona Therapeutics announced the licensing agreement.
Health Landscape
This deal represents a strategic shift by Roche to challenge the long-standing dominance of Eli Lilly and Novo Nordisk in the weight-loss market. It highlights a move toward exploring alternative biological targets like ALK7 to complement standard incretin-based treatments.
This development is in the early stages of research and does not yet change current treatment options for obesity. Any questions regarding new or existing weight-loss medications should be directed to your physician to discuss what is safe and appropriate for your health history.
The takeaway
While Roche is moving to enter the metabolic market, current obesity treatments remain focused on established mechanisms. Discuss any changes to your health plan or interest in emerging research with your healthcare provider.
Further reading
For more on the current options for managing body mass, visit our Weight Loss section.
Live Poll
Do you trust that new pharmaceutical obesity treatments will improve long-term public health?
